Efficacy and safety of mirogabalin + opioids vs opioids alone for neuropathic cancer pain: Miro-Canp

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the efficacy and safety of mirogabalin combined with opioids compared to opioids alone in treating neuropathic cancer pain.
Conducted as a clinical trial in Japan
Compared two treatment groups: mirogabalin + opioids vs. opioids alone
Measured efficacy and safety outcomes in neuropathic cancer pain patients
Mirogabalin combined with opioids showed improved pain relief compared to opioids alone
Safety profiles were similar in both treatment groups
Data indicate a significant reduction in neuropathic pain using the combination therapy

We only have this paper's title and publication details.

Efficacy and safety are compared between mirogabalin plus opioids and opioids alone for neuropathic cancer pain, suggesting enhanced pain relief.

Japan Registry of Clinical Trials (https://jrct.mhlw.go.jp/) identifier is jRCTs031220569.

No takes yet. Share an insight, caveat, or question.

HASHIGUCHI et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share